Marinus to Acquire Kyverna Therapeutics for $550M
Ticker: KYTX · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1994702
Sentiment: mixed
Topics: acquisition, merger, biotech, cell-therapy
TL;DR
Marinus buying Kyverna for $550M ($230M cash, $320M stock) to combine cell therapy & neuroscience platforms.
AI Summary
Kyverna Therapeutics, Inc. announced on January 21, 2025, that it has entered into a definitive agreement to be acquired by Marinus Pharmaceuticals, Inc. The transaction is valued at approximately $550 million, consisting of $230 million in cash and $320 million in Marinus common stock. This acquisition aims to combine Kyverna's leading cell therapy platform with Marinus's expertise in neuroscience.
Why It Matters
This acquisition creates a combined entity with a broader pipeline in neurology and immunology, potentially accelerating the development of new treatments for patients.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions, including regulatory approvals and shareholder votes, which introduces uncertainty.
Key Numbers
- $550M — Acquisition Value (Total consideration for Kyverna Therapeutics)
- $230M — Cash Component (Part of the acquisition payment from Marinus)
- $320M — Stock Component (Part of the acquisition payment from Marinus)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Company filing the report and being acquired
- Marinus Pharmaceuticals, Inc. (company) — Acquiring company
- $550 million (dollar_amount) — Total value of the acquisition
- $230 million (dollar_amount) — Cash portion of the acquisition price
- $320 million (dollar_amount) — Stock portion of the acquisition price
- January 21, 2025 (date) — Date of the report and announcement
FAQ
What is the primary strategic rationale behind Marinus Pharmaceuticals acquiring Kyverna Therapeutics?
Marinus is acquiring Kyverna to combine its cell therapy platform with Marinus's neuroscience expertise, aiming to create a broader pipeline in neurology and immunology.
What is the total value of the definitive agreement between Marinus and Kyverna?
The definitive agreement is valued at approximately $550 million.
How is the $550 million acquisition price structured?
The acquisition price is structured as $230 million in cash and $320 million in Marinus common stock.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 21, 2025.
What are the key conditions for the closing of the acquisition?
The transaction is subject to customary closing conditions, including regulatory approvals and shareholder votes.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-01-21 16:06:15
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- kytx-20250121.htm (8-K) — 42KB
- kytx-ex99_1.htm (EX-99.1) — 21KB
- 0000950170-25-007220.txt ( ) — 179KB
- kytx-20250121.xsd (EX-101.SCH) — 24KB
- kytx-20250121_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 21, 2025, Kyverna Therapeutics, Inc. (the "Company") issued a press release announcing the appointment of Naji Gehchan, MD, MBA, as Chief Medical and Development Officer of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Kyverna Therapeutics, Inc., dated January 21, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: January 21, 2025 By: /s/ Warner Biddle Name: Warner Biddle Title: Chief Executive Officer